BOTHELL, WA and VANCOUVER, Oct. 18, 2011 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced that the Company's third quarter 2011 financial results will be released on Thursday, November 3, 2011 after the NASDAQ Global Market closes at 4:00 p.m. ET, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will discuss the company's financial results and provide an update on the business.
To access the webcast, log on to the Investor Relations page of the OncoGenex website at www.oncogenex.com. Alternatively, you may access the live conference call by dialing (877) 606-1416 (U.S. & Canada) or (707) 287-9313 (International). A webcast replay will be available approximately two hours after the call and will be archived on www.oncogenex.com for 90 days.
About OncoGenex Pharmaceuticals
OncoGenex is a biopharmaceutical company committed to the development
and commercialization of new cancer therapies that address treatment
resistance in cancer patients. OncoGenex has a diverse oncology
pipeline, with each product candidate having a distinct mechanism of
action and representing a unique opportunity for cancer drug
development. OncoGenex and Teva Pharmaceutical Industries
Ltd. (NASDAQ: TEVA) have entered a global collaboration and license
agreement to develop and commercialize OncoGenex' lead drug candidate,
custirsen. Custirsen is currently in Phase III clinical development as
a treatment in men with metastatic castrate-resistant prostate cancer.
The companies plan to begin Phase III development of custirsen in
first-line treatment of advanced, unresectable non-small cell lung
cancer. OGX-427 is in Phase II clinical development; CSP-9222 and
OGX-225 are currently in pre-clinical development. More information is
available at www.OncoGenex.com.
Forward Looking Statements
This press release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995, including, but not limited to,
statements concerning our anticipated product development activities,
such as expected clinical trial initiation. All statements other than
statements of historical fact are statements that could be deemed
forward-looking statements. These statements are based on management's
current expectations and beliefs and are subject to a number of risks,
uncertainties and assumptions that could cause actual results to differ
materially from those described in the forward-looking statements. Such
forward-looking statements are subject to risks and uncertainties,
including, among others, the risk of delays in our expected clinical
trials and the presentation of clinical data and the uncertainties
regarding patient enrollment rates, the risk that new developments in
the rapidly evolving cancer therapy landscape require additional
changes in our clinical trial design or limit the potential benefits of
our product and the other factors described in our risk factors set
forth in our filings with the Securities and Exchange Commission from
time to time, including the Company's Quarterly Report on Form 10-Q for
second quarter ended June 30, 2011. The Company undertakes no
obligation to update the forward-looking statements contained herein or
to reflect events or circumstances occurring after the date hereof,
other than as may be required by applicable law.
SOURCE OncoGenex Pharmaceuticals, Inc.
